Inclusion Criteria:

- Diagnosis of non-resectable, histologically confirmed, epithelial growth factor
receptor(EGFR)-positive or negative colorectal cancer

- WHO Performance status 0 or 1

- Signed written informed consent

- ≥ 18 years of age

- Effective contraception for both male and female subjects if the risk of conception
exists

- Adequate bone marrow function: neutrophil blood cell count (NBC) ≥ 1.5 x 10^9/L,
platelet count ≥ 100 x 10^9/L, hemoglobin ≥ 5.96 mmol/L (10 g/dL)

- Adequate liver and renal function: bilirubin ≤ 1.5 x upper normal level (UNL) and not
increasing more than 25% within the last 4 weeks; ASAT and ALAT ≤ 5 x UNL; serum
creatinine ≤ 1.5 x UNL.

Exclusion Criteria:

- Previous exposure to epidermal growth factor receptor-targeting therapy

- Previous chemotherapy for colorectal cancer except for adjuvant treatment with
progression of disease documented > 6 months after end of adjuvant treatment or 5-FU
in combination with radiotherapy for rectal cancer

- Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before
inclusion.

- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy.

- Investigational agents or participation in clinical trials within 30 days before
start of the treatment in study.

- Clinically relevant coronary disease or myocardial infarction within 12 months before
study entry.

- Peripheral neuropathy > CTC (Common Toxicity Criteria)grade I

- Inflammatory bowel disease

- Previous malignancy (except for colorectal cancer, history of basal cell carcinoma of
skin or pre-invasive carcinoma of the cervix with adequate treatment)

- History of severe psychiatric illness

- Drug or alcohol abuse

- Known hypersensitivity reaction to any of the components of study treatment

- Pregnancy (absence to be confirmed by b-hCG (pregnancy-) test) or lactation period

- Brain metastasis and/or leptomeningeal disease (known or suspected)

- Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease